Archives
Author Archive for: "Joost_content_2019"
Author Archive for: "Joost_content_2019"
This author has not yet written his bio.Meanwhile let's just say that we are proud Joost Bakker contributed with 50 entries.
ISA´s CSO Prof. Cornelis Melief has written a commentary called “Treating the immune system, not the tumour” for MedNous, October 2016: http://www.mednous.com/sites/default/files/CommentaryCornelisMeliefOct2016.pdf
Read more »– Prof. Melief co-chairs Plenary Session 1: Antigens and Vaccines
Leiden, The Netherlands, September 21, 2016 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced that Prof. Cornelis Melief, M.D., and Robert D. Schreiber, Washington University School of Medicine, St. Louis, MO, will jointly chair “Plenary Session 1: Antigens and Vaccines” on September 25, 2016, 8:50 am – 12:00 pm EST at the upcoming CRI-CIMT-EATI-AACR Meeting in New York City.
During the session, Melief will give a presentation titled “Selection of cancer antigens and conditions for success of immunotherapy of
Read more »In June 2016, Kees Melief (CSO of ISA Pharmaceuticals) was named researcher of the week of the Dutch Cancer Society (DCS), a nation-wide organization for cancer-related work in The Netherlands. Read here the interview with him (in Dutch):
https://www.kwf.nl/onderzoek/welk-onderzoek-krijgt-geld/Pages/onderzoeker-van-de-week-Kees-Melief.aspx
Read more »Leiden, The Netherlands, June 03, 2016 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the appointment of Bart Bergstein as Chairman of its Supervisory Board. ISA´s current Chairman Pieter van der Meijden will remain a member of the Supervisory Board.
Bart Bergstein has a strong track record in working with life sciences companies. He is a co-founder of Forbion Capital Partners, a leading European venture capital firm. At Forbion, he invested in numerous healthcare companies and served as a non-executive director on the board of many portfolio companies.
Read more »Leiden, The Netherlands, June 03, 2016 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the appointment of Bart Bergstein as Chairman of its Supervisory Board. ISA´s current Chairman Pieter van der Meijden will remain a member of the Supervisory Board.
Bart Bergstein has a strong track record in working with life sciences companies. He is a co-founder of Forbion Capital Partners, a leading European venture capital firm. At Forbion, he invested in numerous healthcare companies and served as a non-executive director on the board of many portfolio companies.
Read more »Interview with Prof. Cornelis Melief in the latest episode of the Novel Targets podcast:
https://soundcloud.com/noveltargets/episode-12-of-mice-and-men
http://noveltargets.com/2016/05/episode-12-of-mice-and-men/
Interview with Prof. Cornelis Melief in the latest episode of the Novel Targets podcast:
https://soundcloud.com/noveltargets/episode-12-of-mice-and-men
http://noveltargets.com/2016/05/episode-12-of-mice-and-men/
– Granted US patent provides market exclusivity until 2032
Leiden, The Netherlands, April 19, 2016 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced it has been granted a US patent on its AMPLIVANT® technology and compounds (patent no. 9,314,521). The patent ensures market protection in the United States until 2032 and covers the compounds, either as a stand-alone substance or in combination with antigenic peptides, nucleic acids or antibodies. The patent also covers the process for preparing the compounds.
ISA’s AMPLIVANT® technology provides an adjuvant that has been demonstrated
Read more »– Granted US patent provides market exclusivity until 2032
Leiden, The Netherlands, April 19, 2016 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced it has been granted a US patent on its AMPLIVANT® technology and compounds (patent no. 9,314,521). The patent ensures market protection in the United States until 2032 and covers the compounds, either as a stand-alone substance or in combination with antigenic peptides, nucleic acids or antibodies. The patent also covers the process for preparing the compounds.
ISA’s AMPLIVANT® technology provides an adjuvant that has been demonstrated
Read more »– ISA101 clinically effective against HPV-induced vulvar / vaginal lesions and cervical cancer
– Optimum immunotherapy window in cancer identified
Leiden, The Netherlands, April 14, 2016 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, has announced the publication of two peer-reviewed research manuscripts demonstrating the clinical efficacy of its lead product ISA101 in treating high-grade vulvar intraepithelial neoplasia (VIN), and synergy with chemotherapy in cervical cancer. In cervical cancer, the optimum window for treatment with ISA101 starts two weeks after the second chemotherapy cycle has been completed. The multi-center research was conducted in close collaboration with Leiden University Medical Center (LUMC). Publications
Read more »